KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank85
3Y CAGR+49.1%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
+49.1%/yr
Quarterly compound
Percentile
P85
Within normal range
vs 3Y Ago
3.3x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 40.31% |
| Q3 2025 | -36.93% |
| Q2 2025 | -21.96% |
| Q1 2025 | 17.46% |
| Q4 2024 | 1.22% |
| Q3 2024 | -164.27% |
| Q2 2024 | 44.81% |
| Q1 2024 | -39.15% |
| Q4 2023 | 25.84% |
| Q3 2023 | -17.75% |
| Q2 2023 | -144.03% |
| Q1 2023 | 55.24% |
| Q4 2022 | 12.15% |
| Q3 2022 | 11.96% |
| Q2 2022 | -88.37% |
| Q1 2022 | 28.31% |
| Q4 2021 | -10.43% |
| Q3 2021 | -62.68% |
| Q2 2021 | -45.76% |
| Q1 2021 | 4.58% |
| Q4 2020 | -120.64% |
| Q3 2020 | 71.41% |
| Q2 2020 | 3.68% |
| Q1 2020 | -65.35% |
| Q4 2019 | 30.29% |
| Q3 2019 | -5.44% |
| Q2 2019 | 0.83% |
| Q1 2019 | -20.75% |
| Q4 2018 | -32.91% |
| Q3 2018 | 3.72% |
| Q2 2018 | -125.11% |
| Q1 2018 | 483.56% |
| Q4 2017 | -60.38% |
| Q3 2017 | -72.13% |
| Q2 2017 | -23444.06% |
| Q1 2017 | 99.30% |
| Q3 2016 | 77.93% |
| Q2 2016 | -38.97% |
| Q1 2016 | 14.49% |
| Q4 2015 | -15.66% |